Equity · Healthcare
ALLO
NASDAQAllogene Therapeutics (ALLO)
The line runs 2.04 USD on 24 August through 0.6242 USD on 20 November, on a scale from 0.5 to 2.5. Days the market did not trade hold the previous close, flat.
- Market cap
- 216.2M USD
- Revenue, year to Dec 2025
- 0 USD
- EPS, diluted, year to Dec 2025
- −0.87 USD
- Avg volume
- 417.6K
as of Nov 20, 2026
Have Allogene Therapeutics (ALLO) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Allogene Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 21 Oct 2025, show no open-market purchase.
Form 4, 90 days to 22 Nov 2026, newest reported trade 21 Oct 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 21 Oct 2026 | Parker Geoffrey M.CHIEF FINANCIAL OFFICER | Sell | 36,342 | 49K USD |
Which funds hold Allogene Therapeutics (ALLO)?
9 of the 45 institutional funds we track reported a Allogene Therapeutics position for the quarter ended 30 Sep 2026 — a combined 91.7M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Citadel Advisors | Added | 24,558,325 | 39.3M USD | +143.4% |
| Two Sigma Investments | Held (±25%) | 9,012,677 | 14.4M USD | +15.8% |
| Marshall Wace | Added | 7,973,647 | 12.8M USD | +56.5% |
| Renaissance Technologies | Added | 5,232,012 | 8.4M USD | +36.5% |
| Millennium Management | Held (±25%) | 5,115,535 | 8.2M USD | +5.6% |
| D. E. Shaw & Co. | Held (±25%) | 4,261,315 | 6.8M USD | −9.5% |
| Man Group | Trimmed | 518,882 | 830K USD | −26.1% |
| Point72 Asset Management | New position | 368,461 | 590K USD | |
| AQR Capital Management | Trimmed | 261,324 | 418K USD | −87.0% |
What has been filed or recorded for Allogene Therapeutics (ALLO)?
The filings we hold for Allogene Therapeutics, newest first: 6 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 29 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 29 Oct 2026 | Fails to deliver | Shares failed to deliver | 875,974 shares | 1.1M USD notional · 0.253% of shares out |
| 28 Oct 2026 | Fails to deliver | Shares failed to deliver | 189,481 shares | 233K USD notional · 0.055% of shares out |
| 27 Oct 2026 | Fails to deliver | Shares failed to deliver | 666,195 shares | 806K USD notional · 0.192% of shares out |
| 26 Oct 2026 | Fails to deliver | Shares failed to deliver | 9,223 shares | 12K USD notional · 0.003% of shares out |
| 19 Oct 2026 | Fails to deliver | Shares failed to deliver | 1 shares | 1 USD notional · <0.001% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 18,512 shares | 26K USD notional · 0.005% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.15 USD | |
| 30 Sep 2026 | Financials | Total assets | 511.3M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 392.6M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.13 USD | Revenue $5M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.18 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.87 USD | |
| 31 Dec 2025 | Financials | Revenue | 0 USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −190.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.87 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.19 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.23 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.28 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.32 USD | Revenue $0M |
What do people ask about Allogene Therapeutics (ALLO)?
What did Allogene Therapeutics shares close at?0.6242
Allogene Therapeutics closed at 0.6242 USD on 20 Nov 2026, down 5.75% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Allogene Therapeutics’ market cap?216.2M
Allogene Therapeutics is worth 216.2M USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Allogene Therapeutics’ revenue?0
Allogene Therapeutics reported revenue of 0 USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Allogene Therapeutics insiders bought or sold shares recently?1 sale
In the 90 days to 22 Nov 2026, Allogene Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 21 Oct 2025, show no open-market purchase. See Insiders
Which funds own Allogene Therapeutics?9 of 45
9 of the 45 funds we track reported a Allogene Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Two Sigma Investments and Marshall Wace. See Funds
When did Allogene Therapeutics last report earnings?−0.15
Allogene Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.15 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words